Short Interest in Biorestorative Therapies, Inc. (NASDAQ:BRTX) Declines By 62.2%

Biorestorative Therapies, Inc. (NASDAQ:BRTX) saw a large decline in short interest in the month of August. As of August 31st, there was short interest totaling 37,641 shares, a decline of 62.2% from the August 15th total of 99,687 shares. Based on an average trading volume of 175,579 shares, the days-to-cover ratio is presently 0.2 days. Approximately 3.2% of the shares of the company are short sold.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BRTX. Virtu Financial LLC boosted its position in shares of Biorestorative Therapies by 102.4% during the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock valued at $35,000 after acquiring an additional 12,319 shares during the last quarter. Citadel Advisors LLC acquired a new position in Biorestorative Therapies in the 3rd quarter valued at about $152,000. Finally, DRW Securities LLC purchased a new stake in Biorestorative Therapies during the 4th quarter worth approximately $55,000. 69.38% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Monday, August 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Biorestorative Therapies Price Performance

BRTX stock traded up $0.07 during midday trading on Monday, hitting $2.73. 4,820 shares of the stock traded hands, compared to its average volume of 358,183. Biorestorative Therapies has a 1-year low of $2.61 and a 1-year high of $34.60. The stock’s fifty day simple moving average is $4.84 and its 200-day simple moving average is $5.44. The firm has a market cap of $3.77 million, a P/E ratio of -0.13 and a beta of 0.83.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.